No Detail Found!

Comparison of dual vs. triple antithrombotic therapy in non-valvular af and acute coronary syndrome: A malaysian cohort study

Author(s)
Eldowaik Mohamed Salah Saad University of Cyberjaya,Selangor,Malaysia
Zainol Akbar Zainal University of Cyberjaya,Selangor,Malaysia
Shairyzah Ahmed Hisham University of Cyberjaya,Selangor,Malaysia
Sahimi Mohamed Hospital Sultan Idris Shah,Serdang,Malaysia
Pavithira Devi Hospital Sultan Idris Shah,Serdang,Malaysia
Abstract
Objectives: This study aimed to compare Dual Antithrombotic Therapy (DAT) and Triple Antithrombotic Therapy (TAT) concerning bleeding and thrombosis outcomes in Malaysian patients with non-valvular atrial fibrillation (NVAF) and acute coronary syndrome (ACS), considering demographic characteristics and comorbidities. Methodology: A retrospective observational cohort study was conducted at Hospital Serdang from January 1, 2020, to May 1, 2022. A total of 206 patients were selected via purposive sampling and divided into two groups. The TAT group received warfarin, clopidogrel, and aspirin, while the DAT group received warfarin and clopidogrel over a 1-year follow-up. Multivariate logistic regression analysis was employed. Results: A higher incidence of thromboembolic episodes was observed in the DAT group (24.3% vs. 8.7% in the TAT group; adjusted odds ratio (aOR) 4.53, 95% CI 1.806-11.379, P= 0.001), signifying a 4.5-fold increase in thromboembolic events in DAT compared to TAT. Conversely, more bleeding episodes were observed in the TAT group (25.2% vs. 15.5% in the DAT group; aOR 2.22, 95% CI 0.993-4.970, P= 0.52), although the difference was not statistically significant. Conclusion: The DAT protocol showed significantly more thrombosis episodes than the TAT protocol, while TAT exhibited a non-significant increase in bleeding events compared to DAT at one year follow-up in patients with NVAF and ACS.
Publication Details
Page(s) 3-8
Published Journal: Pakistan Heart Journal, Volume: 57, Issue: 1, Year: 2024

Request the full text from PASTIC

Keywords
Acute Coronary Syndrome (ACS), Dual antithrombotic therapy (DAT), Non-valvular atrial fibrillation (NVAF), Triple antithrombotic therapy (TAT)
References
.2018 .Frequency of ischemic stroke subtypes based on toast classification at a tertiary care center in Pakistan. Asian J Neurosurgery, 13(4) : 984-9.
Rashid MH,Yaseen G,Ghaffar U,Khan AA,Kabir A,Aisha A .2020 .Prevalence of Acute Coronary Syndrome and Various Risk Factors in Acute Stroke Patients. Cureus, 12(8) : e9552.
Ahmed I,Nasir A,Shams P,Shahab H,Hassan M,Subhani F .2022 .Clinical characteristics and prognostic factors of atrial fibrillation at a tertiary center of Pakistan-From a South-Asian perspective-A cross-sectional study. Annals Med Surg, 73 : 103128.
Windecker S,Lopes RD,Massaro T,Jones-Burton C,Granger CB,Aronson R .2019 .Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome treated medically or with percutaneous coronary intervention or undergoing elective percutaneous coronary intervention: insights from the AUGUSTUS trial. Circulation, 140(23) : 1921-32.
Suo N,Yang YM,Wang J,Zhang H,Shao XH,Wu S .2022 .Evolving antithrombotic treatment patterns for patients with nonvalvular atrial fibrillation and acute coronary syndrome or underwent percutaneous coronary intervention in China: a crosssectional study. Frontiers Cardiovasc Med, 9 : 846803.
Camm A J,Accetta G,Ambrosio G,Atar D,Bassand JP,Berge E .2017 .Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart, 103(4) : 307-14.
Potpara TS,Lip GY,Dagres N,Crijns HJ,Boriani G,Kirchhof P .2021 .Cohort profile: the ESC EURObservational Research Programme Atrial Fibrillation III (AF III) Registry. Heart Journal - Qual Care Clin Outcomes, 7(3) : 229-37.
Wolfes J,Ellermann C,Frommeyer G .2022 .CCS guidelines on the management of atrial fibrillation. Reviews Cardiovasc Med, 23(2) : 56.
Jr Smith,Feldman SC,Hirshfeld Jr TE,Jacobs JW,Kern AK,King MJ,III SB MJ .2006 .update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous. J Am Coll Cardiol, 47(1) : e1-121.
Hindricks G,Potpara T,Dagres N,Arbelo E,Bax JJ,BlomströmLundqvist C .2021 .ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) The Task Force for the diagnosis and management of atrial fibrillation of the European. Eur Heart J, 42(5) : 373-498.
Moustafa A,Khan M,Saud M,Abdalla AM,Amer B,Muhammad S. Safety .2020 .and efficacy of dual versus triple antithrombotic therapy in Patients with atrial fibrillation undergoing percutaneous coronary intervention: a meta-analysis. Avicenna J Med, 10(4) : 232-40.
van Rein N,Heide-Jørgensen U,Lijfering WM,Dekkers OM,Sørensen HT,Cannegieter SC .2019 .Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy: results from a Nationwide Danish Cohort Study. Circulation, 139(6) : 775-86.
Leon MB,Baim DS,Popma JJ,Gordon PC,Cutlip DE,Ho KK .1998 .A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. New Eng J Med, 339(23) : 1665-71.
Connolly S,Pogue J,Hart R,Pfeffer M,Hohnloser S,Chrolavicius S .2006 .Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet, 367(9526) : 1903-12.
Luo CF,Mo P,Li GQ,Liu SM .2021 .Aspirin-omitted dual antithrombotic therapy in non-valvular atrial fibrillation patients presenting with acute coronary syndrome or undergoing percutaneous coronary intervention: results of a meta-analysis. European Heart Journal - Cardiovasc Pharmacother, 7(3) : 218-24.
Dharma S. Double .2020 .Antithrombotic versus Triple Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome. Inter J Angiol, 29(02) : 081-087.
Dewilde WJ,Oirbans T,Verheugt FW,Kelder JC,De Smet BJ,Herrman JP .2013 .Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet, 381(9872) : 1107-15.
Golwala H,Jackson II L R DN,Piccini JP,Gersh B,Go AS .2016 .Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. Am Heart J, 174 : 29-36.
Li L,Geraghty OC,Mehta Z,Rothwell PM .2017 .Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet, 390(10093) : 490-9.
Mentias A,Briasoulis A,Shantha G,Alvarez P,Vaughan-Sarrazin M .2019 .Impact of heart failure type on thromboembolic and bleeding risk in patients with atrial fibrillation on oral anticoagulation. Am J Cardiol, 123(10) : 1649-53.
Diabetes Reports Current .2012 .. , 13 : 294-304.
.2013 .Diabetes is an independent risk factor for peptic ulcer bleeding: A nationwide population?based cohort study. J Gastroenterol Hepatol, 28(8) : 1295-9.
Moisi MI,Rus M,Bungau S,Zaha DC,Uivarosan D,Fratila O .2020 .Acute coronary syndromes in chronic kidney disease: clinical and therapeutic characteristics. Medicina, 56(3) : 118.
Burlacu A,Genovesi S,Goldsmith D,Rossignol P,Ortiz A,Kalra PA .2018 .Bleeding in advanced CKD patients on antithrombotic medication-a critical appraisal. Pharmacol Res, 129 : 535-43.
0

Citations

0

Downloads

65

Views